HNN3.0
Register
Register
Register

Project cooperationUpdated on 12 January 2026

Advanced 3D-Printed Biomaterial and Bioink Platforms for Disease-Specific cellular models

BioProducts R&D Manager | Regulatory Compliance Officer at COLFEED4Print

Madrid, Spain

About

COLFEED seeks partners to co-develop next-generation organoid platforms using functionalized, easy-to-print biomaterial feedstocks and bioinks for New Approach Methodologies (NAMs) in biomedical research and regulatory drug testing.

COLFEED is a biomaterials manufacturer specializing in 3D printing feedstocks for FDM, with:

  • Patented technology for functionalized, easy-to-print biomaterials

  • Strong experience translating materials into clinical and hospital environments

  • Active collaborations with hospital-based 3D printing units for point-of-care manufacturing

  • Expertise in scalability, reproducibility and manufacturability, key for regulatory acceptance

Within the consortium, COLFEED can lead or contribute to:

  • Development of printing-grade biomaterials and bioinks

  • Design of organoid-supportive scaffolds and matrices

  • Integration of manufacturing workflows compliant with regulatory expectations

  • Technology transfer toward clinical and industrial environments

Partners may contribute to organoid biology, analytical validation, disease modeling, clinical relevance or regulatory alignment.

Topic

  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

Similar opportunities

  • Project cooperation

    Climate-Neutral Point-of-Care 3D Printed Regenerative Bone Implants for Resilient Healthcare Systems

    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-04: Towards climate resilient, prepared and carbon neutral populations and healthcare systems

    Lucia Gallego

    BioProducts R&D Manager | Regulatory Compliance Officer at COLFEED4Print

    Madrid, Spain

  • Project cooperation

    Looking for Consortium

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Oscar Castano

    Tenured Associate Professor at Universitat de Barcelona

    Barcelona, Spain

  • Project cooperation

    Organoids and bionanomaterials customization

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

    Fabrizio Gelain

    PI at IRCCS Casa Sollievo della Sofferenza

    San Giovanni Rotondo, Italy